Psychedelic medicine is currently undergoing a period of scientific and regulatory acceleration. This article analyzes the current state of therapeutic use for substances such as MDMA, psilocybin, ketamine, ayahuasca, and ibogaine within the European and Spanish contexts.
In brief
- The therapeutic landscape for psychedelic substances is evolving rapidly, moving from clinical trials to regulated applications in countries like Australia and the United States.
- Ketamine already has an established clinical presence in Spain via esketamine, while MDMA and psilocybin are on the horizon for 2026–2027 under strict conditions.
- Therapeutic success does not reside solely in the molecule, but in a structured process of preparation, active support, and subsequent integration.
The field of mental health is undergoing an unprecedented transformation. For decades, substances with profound perceptual properties were marginalized or criminalized, but today they are experiencing a scientific renaissance driven by the need to address disorders resistant to conventional treatment. From post-traumatic stress to major depression and chronic pain, new therapeutic pathways are emerging at the intersection of advanced pharmacology and deep psychotherapy.
However, this transition is neither automatic nor uniform. While some healthcare systems are moving toward models of regulated access, others are proceeding with caution in the face of a legal framework that is still under construction. In this context, understanding psychedelic medicine requires distinguishing between media hype and rigorous clinical evidence, separating marketing promises from validated protocols.
The state of the art: between evidence and practice
Current scientific literature offers clear signs of efficacy for compounds such as psilocybin in treatment-resistant depression or MDMA in post-traumatic stress disorder. However, the operational reality differs by geography. Australia has been a pioneer by authorizing the use of MDMA and psilocybin under exceptional conditions since July 2023, a notable milestone that anticipates broader regulatory changes.
In Europe, the situation is more nuanced. The United States and Canada have developed robust “compassionate use” models, while Switzerland and Israel are exploring similar paths. Spain, for its part, has a consolidated presence of racemic ketamine in private clinics that integrate psychotherapy, although esketamine (Spravato) remains an authorized symptomatic treatment without a comprehensive therapeutic indication according to current European technical data sheets.
It is crucial to understand that access to these substances does not guarantee automatic results. The literature clearly distinguishes between the isolated drug and the assisted process. Clinical efficacy depends on structural variables: appropriate patient selection, a safe therapeutic setting, and, fundamentally, a post-experience integration phase that consolidates cognitive and affective changes.
Ketamine: utility with nuances
Ketamine currently occupies a central place in assisted clinical practice. Its mechanism of action, distinct from other classic psychedelics (an NMDA receptor blocker versus a serotonergic agonist), allows for rapid and effective applications for depression and chronic pain.
In the Spanish landscape, the availability of clinics offering ketamine-assisted psychotherapy has grown notably. However, it is imperative to distinguish between these integrated models and the purely symptomatic use prescribed in some medical contexts. The literature warns of risks associated with unsupervised use or use without adequate integration, including severe dissociation, long-term cognitive effects if used with high frequency, and the need to rule out prior psychiatric contraindications.
The expansion of the American model into Europe faces specific cultural and regulatory barriers. Advertising restrictions in the healthcare sector, differences in risk-benefit assessment by European agencies, and episodes of shortages or variability in product quality are factors that explain why the North American experience is not simply replicated.
Psilocybin, MDMA, and ibogaine: regulated horizons
Psilocybin and MDMA represent the next steps on the regulatory ladder. If clinical and administrative conditions are met as projected by the international scientific community, their availability could extend to Spain by 2026–2027. These compounds require precise doses and a controlled environment to minimize risks of acute anxiety or maladaptive experiences.
On the other hand, substances such as ayahuasca and ibogaine present additional challenges due to their pharmacological and cultural complexity. Ayahuasca, a plant mixture containing endogenous DMT and natural MAOIs, requires a specific ritual or therapeutic context for safe administration. Ibogaine, used in South Africa and New Zealand under strict protocols, offers potential for the treatment of addictions but requires careful management of its cardiovascular effects.
Harm reduction and critical reading
Clinical prudence is the compass in this territory. Before considering any intervention with psychedelic substances, the following aspects must be rigorously evaluated:
- Information references: Prioritize updated clinical guidelines and peer-reviewed studies over anecdotal testimonials or commercial promotions.
- Medical contraindications: Evaluate psychiatric history, concomitant use of medications (especially antidepressants that can induce serotonin syndrome), and physical comorbidities.
- Safe environment: Ensure a controlled physical space, the presence of trained personnel, and defined emergency protocols.
- Realistic expectations: Recognize that these therapies are not magic bullets. Results vary by individual and require time to consolidate.
Modern toxicology underscores the low organic toxicity of these compounds compared to other psychoactive substances, but this does not exempt one from professional supervision. The distinction between personal possession and trafficking remains a critical point in the Spanish legal framework, where administrative sanctions can be applied even without commercial intent.
Who this approach is useful for
Patients seeking alternatives to conventional treatments: understanding real indications, potential risks, and the difference between isolated pharmacological intervention and complete psychotherapeutic processes allows them to make informed decisions.
Mental health professionals: they need a clear synthesis of basic pharmacology, regulatory status, and practice models to integrate these tools into their therapeutic arsenal or refer cases appropriately.
Health managers and public decision-makers: they require a comparative framework and regulatory analysis to design safe services that balance scientific innovation with patient protection.
Editorial conclusion
Psychedelic medicine is not a passing fad, but a necessary response to the historical limitations of traditional psychiatry. However, its implementation requires scientific rigor, professional ethics, and communicative transparency.
As we move toward a horizon where more flexible regulations could enable new therapeutic pathways, it is fundamental to maintain a critical eye that distinguishes between solid evidence and unfounded speculation. The true revolution does not reside in the substances themselves, but in how we use science to alleviate human suffering without falling into dangerous simplifications.
At Psiconáutica, we understand that awareness regarding these compounds must be accompanied by social and personal responsibility. Fostering an informed dialogue between patients, clinicians, and civil society is the first step toward a more humane and effective medicine.
